Company intelligence / Profile preview

Nuclidium

Ownership: Private
Development stage: Phase 1

Overview

Nuclidium has advanced several copper-based radiodiagnostic and therapeutic agents into Phase 1 clinical trials. Their lead programs target high-unmet need solid tumors using proprietary copper radioisotopes for both diagnosis and therapy. Early clinical data are not yet published but the company claims improved safety/efficacy profiles with their approach.

Therapeutic areas: OncologyEndocrinologyInfectious Diseases
Modalities: RadiopharmaceuticalDiagnostic radiopharmaceuticalRadionuclide drug conjugate
Industry: Biotech

Drug pipeline

10 assets

61Cu-NODAGA-LM3

9 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with partners across interdisciplinary fields to optimize production processes and expand supply network

Beyond the preview

Go deeper on Nuclidium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclidium.

Explore the full profile